Catalent Company Insiders

CTLT Stock  USD 57.98  0.16  0.28%   
Slightly above 60% of Catalent's corporate insiders are selling. The analysis of insiders' sentiment of trading Catalent stock suggests that many insiders are alarmed at this time. Catalent employs about 18 K people. The company is managed by 51 executives with a total tenure of roughly 337 years, averaging almost 6.0 years of service per executive, having 352.94 employees per reported executive. Breaking down Catalent's management performance can provide insight into the firm performance. Note that employee analysis is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Catalent's future performance.
John Chiminski  Chairman
Chairman of the Board, Chief Executive Officer
Chinh Chu  Chairman
Chairman of the Board
Aris Gennadios  President
President - Softgel Technologies

Catalent's Insider Buying Vs Selling

40

 
Selling
 
Buying
2023-08-31Michelle R RyanAcquired 1000 @ 49.98View
2023-08-30John J GreischAcquired 21000 @ 50.24View
2023-08-24Steven L FasmanDisposed 817 @ 44.65View
2023-08-01Ricardo PravdaDisposed 269 @ 47.56View
2023-05-01Mario GargiuloDisposed 678 @ 49.86View
Monitoring Catalent's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Catalent's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Catalent. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Catalent's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.

Catalent Return on Sales

(0.0342)

  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.

Catalent Management Team Effectiveness

Return on Investment is likely to drop to -2.08 in 2024. Return on Average Assets is likely to drop to -0.03 in 2024. At this time, Catalent's Current Liabilities is comparatively stable as compared to the past year. Tax Liabilities is likely to gain to about 97.7 M in 2024, whereas Total Liabilities is likely to drop slightly above 6 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.

Catalent Quarterly Income Before Tax

(181 Million)

Issuance Purchase of Equity Shares is likely to gain to about 3.7 M in 2024, whereas Weighted Average Shares is likely to drop slightly above 191.9 M in 2024.

Catalent Workforce Comparison

Catalent is rated second in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 38,443. Catalent totals roughly 18,000 in number of employees claiming about 47% of equities under Health Care industry.

Catalent Profit Margins

The company has Profit Margin (PM) of (0.32) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.

Catalent Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalent insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalent's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Catalent insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Catalent Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Catalent Price Series Summation is a cross summation of Catalent price series and its benchmark/peer.
.

Catalent Notable Stakeholders

A Catalent stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Catalent often face trade-offs trying to please all of them. Catalent's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Catalent's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John ChiminskiChairman of the Board, Chief Executive OfficerProfile
Chinh ChuChairman of the BoardProfile
Aris GennadiosPresident - Softgel TechnologiesProfile
Steven FasmanSenior Vice President General Counsel and Corporate SecretaryProfile
Scott HoultonPresident - Development and Clinical ServicesProfile
Wetteny JosephChief Financial Officer, Senior Vice PresidentProfile
Alessandro MaselliSenior Vice President - Global OperationsProfile
Charles LickfoldSenior Vice President, Chief Information OfficerProfile
Aristippos GennadiosPresident - Softgel & Oral TechnologiesProfile
Ricardo PravdaChief Human Resource Officer, Senior Vice PresidentProfile
Lance MiyamotoSenior Vice President - Human ResourcesProfile
Jonathan ArnoldPresident - Oral & Specialty DeliveryProfile
Ricky HopsonDivision PresidentProfile
Christine DolanSenior Vice President - Product DevelopmentProfile
Scott GuntherSenior Vice President - Quality & Regulatory AffairsProfile
Barry LittlejohnsPresident - Advanced Delivery TechnologiesProfile
Matthew WalshCFO and Executive VPProfile
Matti MasanovichSenior CFOProfile
Sharon JohnsonSr. VP of Quality, Product Devel., and Regulatory AffairsProfile
Stephen LeonardSr. VP of Global OperationsProfile
William DownieSr. VP of Global Marketing and SalesProfile
Bruce McEvoyDirectorProfile
James QuellaDirectorProfile
Gregory LucierIndependent DirectorProfile
Rolf ClassonIndependent DirectorProfile
Michael BarberIndependent DirectorProfile
Martin CarrollDirectorProfile
Rosemary CraneIndependent DirectorProfile
Peter ZippeliusIndependent DirectorProfile
Donald MorelIndependent DirectorProfile
John GreischIndependent DirectorProfile
Christa KreuzburgIndependent DirectorProfile
Madhavan BalachandranIndependent DirectorProfile
Lucier GregoryDirectorProfile
Melvin BoothDirectorProfile
Jack StahlLead Independent DirectorProfile
Uwe RohrhoffDirectorProfile
Thomas CastellanoVP of Fin. and Investor Relations and TreasurerProfile
Michael HatzfeldVP OfficerProfile
Joseph JDGeneral VPProfile
Paul SurdezVice RelationsProfile
Kay SchmidtSenior Vice President - Technical OperationsProfile
Karen SantiagoVP OfficeProfile
Julien MeissonnierVP OfficerProfile
Ricci WhitlowPresident - Clinical Supply ServicesProfile
Z MahdaviVice President of Open Innovation, Biologics, Cell and Gene TherapyProfile
John MBAExecutive BoardProfile
Steven EsqCorp VPProfile
Karen FlynnPresident - Biologics and Chief Commercial OfficerProfile
Michael GrippoSenior Vice President - Strategy and Corporate DevelopmentProfile
J CarrollIndependent DirectorProfile

About Catalent Management Performance

The success or failure of an entity such as Catalent often depends on how effective the management is. Catalent management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Catalent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Catalent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return on Investment(2.03)(2.08)
Return on Average Assets(0.03)(0.03)
Return on Average Equity(0.05)(0.05)
Return on Invested Capital(0.01)(0.01)
Return on Sales(0.03)(0.03)
The data published in Catalent's official financial statements usually reflect Catalent's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Catalent. For example, before you start analyzing numbers published by Catalent accountants, it's critical to develop an understanding of what Catalent's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Catalent's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Catalent's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Catalent's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalent. Please utilize our Beneish M Score to check the likelihood of Catalent's management manipulating its earnings.

Catalent Workforce Analysis

Traditionally, organizations such as Catalent use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Catalent within its industry.

Catalent Manpower Efficiency

Return on Catalent Manpower

Revenue Per Employee206.5K
Revenue Per Executive83.8M
Net Loss Per Employee13.3K
Net Loss Per Executive5M
Working Capital Per Employee65.1K
Working Capital Per Executive23M
Today, most investors in Catalent Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Catalent's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Catalent per employee as a starting point in their analysis.

Net Income Per Employee

(13,284.43)

At this time, Catalent's Net Income Per Employee is comparatively stable as compared to the past year.

Revenue Per Employee

206,452

At this time, Catalent's Revenue Per Employee is comparatively stable as compared to the past year.
When determining whether Catalent is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Catalent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Catalent Stock. Highlighted below are key reports to facilitate an investment decision about Catalent Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Catalent Stock analysis

When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.15)
Earnings Share
(7.18)
Revenue Per Share
22.623
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.01)
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.